학술논문
A Pilot, Phase II, Randomized, Open-Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab-Paclitaxel to That of Solvent-Based Paclitaxel as the First-Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2-Negative Metastatic Breast Cancer
Document Type
Article
Author
Source
In: Oncologist . (Oncologist, 1 November 2019, 24(11):e1024-e1033)
Subject
Language
English
ISSN
1549490X
10837159
10837159